Indication
Stage IIIA Lung Cancer
27 clinical trials
30 products
22 drugs
Product
EMB-01Product
OsimertinibClinical trial
A Phase Ib/II, Open-Label, Multi-Center Study of EMB-01 in Combination With Osimertinib in Patients With Advanced/Metastatic EGFR Mutant Lung CancerStatus: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2025-02-28
Drug
CisplatinClinical trial
Randomized Phase II Study of Standard Chemotherapy With Docetaxel With or Without Bintrafusp Alfa in Patients With Advanced NSCLC After Progressing on a Combination of Anti-PD-1/PD-L1 Agents and ChemotherapyStatus: Terminated, Estimated PCD: 2023-12-31
Product
Bintrafusp AlfaDrug
DocetaxelClinical trial
A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Drug
AN0025Drug
TiragolumabProduct
PapaverineProduct
PemetrexedClinical trial
Qualitative Study on Experiences Related to Anorexia and the Effects of Anamorelin and Placebo in Advanced Non-Small-Cell Lung Cancer Patients With Anorexia-Cachexia: A Preliminary StudyStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
AnamorelinClinical trial
A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesStatus: Completed, Estimated PCD: 2023-11-30
Drug
AbexinostatClinical trial
Phase II Clinical Trial Evaluating Intravenous AZD9150 (Antisense STAT3) With MEDI4736 (Anti-PD-L1) in Patients With Advanced Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Drug
DanvatirsenClinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)Status: Recruiting, Estimated PCD: 2025-02-24
Drug
cyclophosphamideClinical trial
An Open-Label Phase 1b Dose-Finding Trial Evaluating the Safety of Niraparib and Temozolomide and Atezolizumab in Participants With Advanced Solid Tumors and Expansion to a Phase 2 Trial Comparing the Effects of Niraparib and Temozolomide Plus Atezolizumab vs. Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (TRIO-US L-06)Status: Recruiting, Estimated PCD: 2025-01-03
Drug
AtezolizumabProduct
NiraparibProduct
TMZProduct
PembrolizumabClinical trial
An Open-label, Single-Center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted AntibodiesStatus: Recruiting, Estimated PCD: 2025-06-01
Product
AvelumabProduct
DurvalumabProduct
NivolumabProduct
PlinabulinProduct
Neoantigen Peptide VaccineClinical trial
A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer - (IM-BATTLE-2 Program)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
TrametinibClinical trial
Endobronchial Ultrasound Transbronchial Needle Guided Interstitial Photodynamic Therapy for Palliation of Locally Advanced Lung Cancer and Advanced Cancers Obstructing the Airway -Phase I/IIStatus: Recruiting, Estimated PCD: 2030-02-12
Product
PorfimerClinical trial
A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination With Anti-PD1 Therapy in Patients With Advanced NSCLC or Squamous Head and Neck CancerStatus: Recruiting, Estimated PCD: 2027-12-09
Clinical trial
Phase 1 Trial of Umbilical Cord Blood Natural Killer Cells (CB-NK) Expressing Soluble IL-15 (sIL-15) and PD-L1 +/- Atezolizumab in Non-Small Cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint InhibitorsStatus: Active (not recruiting), Estimated PCD: 2025-09-30
Product
Antineoplastic Immune CellProduct
FludarabineClinical trial
Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)Status: Recruiting, Estimated PCD: 2024-09-30
Drug
GemcitabineClinical trial
A Pilot Trial of Electronic Cigarettes in Patients Diagnosed With Cancers of the Head, Neck, and LungStatus: Withdrawn, Estimated PCD: 2024-01-31
Product
Nicotine ReplacementDrug
AbraxaneClinical trial
Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)Status: Active (not recruiting), Estimated PCD: 2025-05-30
Clinical trial
Single Arm Phase II Trial Using Canakinumab for the Prevention of Lung Cancer (Can-Prevent-Lung)Status: Recruiting, Estimated PCD: 2025-12-31
Product
CanakinumabClinical trial
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
UTD1Drug
doxorubicinClinical trial
A Phase II Study of Subcutaneous Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial ModelStatus: Recruiting, Estimated PCD: 2025-12-07
Product
AtezolizumabDrug
fluorouracilProduct
IpilimumabProduct
IrinotecanDrug
mFOLFOX6Drug
T-VECProduct
OlaparibDrug
FOLFOXIRIDrug
SelinexorProduct
TopotecanClinical trial
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)Status: Active (not recruiting), Estimated PCD: 2027-02-01
Drug
lenalidomideClinical trial
A Phase 1b Neoadjuvant Trial of Sirolimus Followed by Durvalumab (MEDI4736) in Resectable Non-small Cell Lung CancerStatus: Terminated, Estimated PCD: 2022-11-04
Drug
rapamycinProduct
Nogapendekin AlfaProduct
RamucirumabClinical trial
Phase I/II Trial of Anti-CTLA4-NF mAb (BMS-986218) in Combination With Nivolumab and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2025-05-27
Product
BMS-986218Clinical trial
A Phase Ib/II Trial to Evaluate Safety, Tolerability and Efficacy of Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for Patients With EGFR-Mutant Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Product
LY3295668Drug
OsimertinibClinical trial
A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
LurbinectedinDrug
TocilizumabClinical trial
A Pilot Trial of Ipilimumab-Nivolumab in Local-Regionally Advanced Non Small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 0 Study of CIMAvax-EGF Vaccine in Patients Who Are at High Risk for Lung Cancer and Lung Cancer Survivors at Risk for RecurrenceStatus: Recruiting, Estimated PCD: 2024-11-22